CagriSema Arrives: Phase 3 Data Suggest the Amylin–GLP-1 Combo Edges Past Semaglutide

Semaglutide works on the GLP-1 receptor — it slows gastric emptying, modulates appetite, and improves insulin response. Cagrilintide works on the amylin receptor, a parallel satiety pathway that the body normally co-secretes with insulin. The thesis behind CagriSema is straightforward: two complementary brakes on appetite and glucose should outperform one. The REIMAGINE 2 investigators state this explicitly, describing cagrilintide and semaglutide as having complementary effects on glycaemic control and bodyweight.

That biological rationale has existed for years. What's new is that it has now been tested at phase 3 scale, in the format regulators actually care about: large, double-blind, randomized trials with active comparators rather than placebo alone.

REIMAGINE 1 was the cleaner of the two designs: a 40-week, double-blind, placebo-controlled phase 3a study in adults with type 2 diabetes inadequately controlled by diet and exercise alone — meaning no background metformin, no SGLT2 inhibitor, just lifestyle. Participants were randomized to receive once-weekly cagrilintide-semaglutide at either 2.4 mg of each component or 1.0 mg of each, against matched placebo, with HbA1c at week 40 as the primary endpoint, according to the REIMAGINE 1 protocol.

REIMAGINE 2 is the trial that matters most for the "does it beat semaglutide?" question. It ran 68 weeks across 30 countries in people with type 2 diabetes already on metformin, with or without an SGLT2 inhibitor. The study randomized participants into six active arms plus placebo: CagriSema at two dose levels (2.4 mg / 2.4 mg and 1.0 mg / 1.0 mg), semaglutide alone at both 2.4 mg and 1.0 mg, and cagrilintide alone at 2.4 mg. That four-way active comparison — combo versus each monotherapy, at matched doses — is what gives the readout its weight, per the REIMAGINE 2 design.

Three honest takeaways. First, the population studied was adults with type 2 diabetes, not metabolically healthy men chasing body composition. Extrapolating from a glycemic trial to off-label weight optimization is exactly the kind of leap the evidence does not yet support. Second, the comparator that matters — semaglutide at 2.4 mg, the dose used in obesity care — is built into REIMAGINE 2's design, which is a meaningful upgrade from the placebo-only framing of most earlier peptide trials. Third, "better than semaglutide" in a trial doesn't automatically translate to "better for you." Combination therapy stacks two appetite-suppressing mechanisms, and the relevant question for any individual is how much incremental benefit justifies a more complex side-effect profile and, eventually, a more complex price tag.

Both trials report safety as a secondary objective. Specific tolerability comparisons — particularly nausea, vomiting, and discontinuation rates across arms — will be the practical determinant of whether CagriSema becomes the default or stays a tier-two option for patients who plateau on semaglutide.

Two simultaneous phase 3 trials, double-blinded, with active comparators, published in a top-tier endocrinology journal — that is genuinely high-quality evidence by the standards of the peptide space. But moderate is the right word for the rating. The combination has been tested in two trials, in one disease state, by the manufacturer that developed it. Independent replication, longer follow-up beyond 68 weeks, and direct comparisons against tirzepatide (the dual agonist that already raised the bar) are all still to come. None of that is a reason to dismiss the readout. It is a reason not to over-read it.

The short version: the post-semaglutide era didn't start with a miracle drug. It started with a carefully designed combination, a pair of well-run trials, and a readout that pushes the field forward without resolving it. That's how progress in this space is supposed to look.